ArticleMedical review (2021)2023
Application and prospect of artificial intellingence in diabetes care.
Article in Medical review (2021), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 13 citations in OpenAlex.
- Application study of an artificial intelligence and big data-based personalized chronic disease management model for diabetes patients.Frontiers in public health · 2026Article
- Association of overweight with treatment outcomes in pulmonary tuberculosis.BMC infectious diseases · 2025Article
- Correlation Between Blood Glucose Level and Cerebral Small Vessel Disease Markers in Neurologically Asymptomatic, Nondiabetic Individuals.Aging medicine (Milton (N.S.W)) · 2025Article
- Predictive Model for In-Hospital Death in Older Patients with Type 2 Diabetes Mellitus: A Multicenter Retrospective Study in Southwest China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Federated multimodal AI for precision-equitable diabetes care.Frontiers in digital health · 2025Review
- Magnetic resonance imaging classification in a percutaneous needle injury rat model of intervertebral disc degeneration.Journal of orthopaedic surgery and research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Diabetes is one of the fastest-growing non-communicable diseases, becoming an important public health concern worldwide as well as in China. Currently, China has the largest population living with diabetes. Artificial intelligence (AI) is a fast-growing field and its applications to diabetes could enable the delivery of better management services for people with diabetes. This perspective summarized the latest findings of digital technologies and AI use in the following areas of diabetes care, mainly including screening and risk predictions of diabetes and diabetic complications, precise monitoring and intervention combined with new technologies, and mobile health application in self-management support for people with diabetes. Challenges to promote further use of AI in diabetes care included data standardization and integration, performance of AI-based medical devices, motivation of patients, and sensitivity to privacy. In summary, although the AI applications in clinical practice is still at an early stage, we are moving toward a new paradigm for diabetes care with the rapid development and emerging application of AI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.